Pardoll, Drew M.

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 9,377

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 7,945

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,645

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer

Cytokine Signaling Pathways and InteractionsImmune cells in cancer

Cited by 4,383

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 4,229

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,733

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,324

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,222

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,157

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,099

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 2,022

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses

Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine

Gut microbiota and healthT-cell and B-cell Immunology

Cited by 1,812

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,647

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 1,595

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 1,487

The Central Role of CD4+ T Cells in the Antitumor Immune Response

Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 1,345

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 1,337

Role of LAG-3 in Regulatory T Cells

Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 1,325

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 1,258

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene

Angiogenesis and VEGF in CancerCytokine Signaling Pathways and Interactions

Cited by 1,207

Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria

Dejea, C. M., Fathi, P., Craig, J. M., Boleij, A., Taddese, R., Geis, A. L., Wu, X., DeStefano Shields, C. E., Hechenbleikner, E. M., Huso, D. L., et al. (2018) · Science

Gut microbiota and healthBacterial biofilms and quorum sensing

Cited by 1,105

Neoadjuvant checkpoint blockade for cancer immunotherapy

Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,001